English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

There is conflicting data regarding the role of PBAF complex mutations and response to immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid tumors. We assess the prevalence of PBAF complex mutations from two large cohorts including the pan-cancer TCGA project ( n  = 10,359) and the MSK-IMPACT pan-cancer immunotherapy cohort ( n  = 3700). Across both cohorts, PBAF complex mutations, predominantly  PBRM1  mutations, are most common in ccRCC. In multivariate models of ccRCC patients treated with ICB ( n  = 189), loss-of-function (LOF) mutations in  PBRM1  are not associated with overall survival (OS) (HR = 1.24,  p  = 0.47) or time to treatment failure (HR = 0.85,  p  = 0.44). In a series of 11 solid tumors ( n  = 2936), LOF mutations are not associated with improved OS in a stratified multivariate model (HR = 0.9,  p  = 0.7). In a current series of solid tumors treated with ICB, we are unable to demonstrate favorable response to ICB in patients with PBAF complex mutations.

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response